Wilson Sonsini Continuesto Grow in London.

Wilson Sonsini announced the addition of three partners in London as the firm continues to expand and extend its London-based service offerings. For more information, see our news release.

Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.

For more than six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Quick Links

Introducing Neuron, a new platform that streamlines, automates, and digitizes the typical legal processes along a start-up’s journey

Neuron Website

Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Alerts

FinCEN Issues ‘First-of-its-Kind’ Order Against Crypto Asset Exchange Linked to Illicit Russian Activity

Alerts

California AG Targets Mobile Apps for Failing to Honor or Provide Mechanism for Opt-Out Requests

Press Releases

Wilson Sonsini Adds Former SEC Official Tamara Brightwell to Public Company Practice

Leading Matters

Client Highlights

Wilson Sonsini Advises Spatial Labs on $10 Million Seed Financing

On January 26, 2023, Spatial Labs, a web3 infrastructure and hardware company founded by Iddris Sandu, announced $10 million in seed funding led by Blockchain Capital with participation from Marcy Venture Partners, the firm co-founded by Jay-Z. Wilson Sonsini Goodrich & Rosati advised Spatial Labs on the transaction.

Learn More

Client Highlights

Wilson Sonsini Represents Cheche Technology in Business Combination with Prime Impact Acquisition I

On January 30, 2023, Cheche Technology Inc. (Cheche Technology), China’s leading automotive insurance technology platform, and Prime Impact Acquisition I (Prime Impact), a publicly traded special purpose acquisition company, announced that they have entered into a definitive agreement for a business combination between Cheche Technology and Prime Impact. Upon the completion of the business combination, the combined company, Cheche Group Inc., will become a publicly traded company on the Nasdaq Stock Market. Wilson Sonsini Goodrich & Rosati represented Cheche Technology in this transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Alleviant Medical on $75 Million Financing

On January 26, 2023, Alleviant Medical, Inc., a privately-held medical device company developing a no-implant interatrial shunt for heart failure, announced the closing of a $75 million equity financing co-led by S3 Ventures and RiverVest Venture Partners. The lead investors in this new funding round are joined by Vensana Capital, Longview Ventures, TMC Venture Fund, and a strategic investor, in addition to Gilmartin Capital, ShangBay Capital, and another undisclosed strategic investor. This financing will fund the company’s global pivotal trial, ALLAY-HF (Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure). ALLAY-HF is designed to demonstrate the safety and effectiveness of the Alleviant System for the treatment of heart failure through left atrial decompression. Wilson Sonsini Goodrich & Rosati represented Alleviant Medical in the transaction.

Learn More

Client Highlights

Firm Advises Pacific Biosciences of California on Upsized Stock Offering

On January 24, 2023, life sciences technology company Pacific Biosciences of California Inc announced that it has priced a 17.5 million share secondary stock offering at $10 per share. The transaction will raise $175 million, which was upsized from the original size of $150 million. Wilson Sonsini Goodrich and Rosati advised Pacific Biosciences on the transaction.

Learn More

Client Highlights

Wilson Sonsini Represents QuantaSing in $40 Million IPO

On January 25, 2023, QuantaSing Group Limited announced the pricing of its initial public offering of 3,250,000 American depositary shares (ADSs) at a price to the public of US$12.50 per ADS for a total offering size of approximately US$40.6 million (or US$46.7 million assuming the underwriters exercise their option to purchase additional ADSs in full). The ADSs began trading on the Nasdaq Global Market on January 25, 2023, under the symbol "QSG." This transaction is among the largest U.S. initial public offerings for China-based issuers since August 2021. Citigroup Global Markets Inc. and China International Capital Corporation Hong Kong Securities Limited acted as representatives of the underwriters of this offering. Wilson Sonsini Goodrich & Rosati acted as U.S. counsel to QuantaSing in this offering.

Learn More

Client Highlights

Wilson Sonsini Advises FATMAP on Acquisition by Strava

On January 24, 2023, fitness-based subscription platform Strava announced that it had acquired mobile app FATMAP. Wilson Sonsini Goodrich and Rosati advised FATMAP on the transaction.

Learn More

See More Leading Matters

2022 Antitrust Year in Review

We are proud to share the 2022 Antitrust Year in Review, which discusses significant developments in antitrust law, policy, and enforcement over the past year. First, the report spotlights recent outcomes in court for U.S. agency enforcement litigation and discusses major changes in the law that create substantial new antitrust obligations, as well as updated policy and enforcement guidelines. Then, the merger enforcement section describes significant merger control activity by enforcers in the U.S., EU, and UK, and the civil conduct enforcement section outlines enforcer activity in investigating and challenging non-merger conduct. Finally, the report provides an update on global cartel enforcement policy and activity, and concludes with a survey of significant private antitrust litigation in the United States and UK.